139 related articles for article (PubMed ID: 15849223)
1. Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients.
Schwinger W; Klass V; Benesch M; Lackner H; Dornbusch HJ; Sovinz P; Moser A; Schwantzer G; Urban C
Ann Oncol; 2005 Jul; 16(7):1199-206. PubMed ID: 15849223
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.
Blaney SM; Needle MN; Gillespie A; Sato JK; Reaman GH; Berg SL; Adamson PC; Krailo MD; Bleyer WA; Poplack DG; Balis FM
Clin Cancer Res; 1998 Feb; 4(2):357-60. PubMed ID: 9516923
[TBL] [Abstract][Full Text] [Related]
3. Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.
Büyükkapu Bay S; Kebudi R; Görgün O; Zülfikar B; Darendeliler E; Çakır FB
J Oncol Pharm Pract; 2019 Sep; 25(6):1343-1348. PubMed ID: 30080131
[TBL] [Abstract][Full Text] [Related]
4. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.
Osenga KL; Hank JA; Albertini MR; Gan J; Sternberg AG; Eickhoff J; Seeger RC; Matthay KK; Reynolds CP; Twist C; Krailo M; Adamson PC; Reisfeld RA; Gillies SD; Sondel PM;
Clin Cancer Res; 2006 Mar; 12(6):1750-9. PubMed ID: 16551859
[TBL] [Abstract][Full Text] [Related]
5. Combination interleukin-2 and doxorubicin in advanced adult solid tumors: circumvention of doxorubicin resistance in soft-tissue sarcoma?
Le Cesne A; Vassal G; Farace F; Spielmann M; Le Chevalier T; Angevin E; Valteau-Couanet D; Fizazi K; Cojean I; Llombard A; Tursz T; Escudier B
J Immunother; 1999 May; 22(3):268-77. PubMed ID: 10335487
[TBL] [Abstract][Full Text] [Related]
6. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer.
Kammula US; White DE; Rosenberg SA
Cancer; 1998 Aug; 83(4):797-805. PubMed ID: 9708948
[TBL] [Abstract][Full Text] [Related]
7. Long-term IL-2 therapy after transplantation of T cell depleted stem cells from alternative donors in children.
Schlegel P; Teltschik HM; Pfeiffer M; Handgretinger R; Schumm M; Koscielniak E; Feuchtinger T; Klingebiel T; Bader P; Schlegel PG; Greil J; Lang P
Best Pract Res Clin Haematol; 2011 Sep; 24(3):443-52. PubMed ID: 21925097
[TBL] [Abstract][Full Text] [Related]
8. Continuous infusion of interleukin-2 in children with refractory malignancies.
Ribeiro RC; Rill D; Roberson PK; Furman WL; Pratt CB; Brenner M; Crist WM; Pui CH
Cancer; 1993 Jul; 72(2):623-8. PubMed ID: 8319196
[TBL] [Abstract][Full Text] [Related]
9. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F
Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of irinotecan in pediatric patients: a pediatric oncology group study.
Blaney S; Berg SL; Pratt C; Weitman S; Sullivan J; Luchtman-Jones L; Bernstein M
Clin Cancer Res; 2001 Jan; 7(1):32-7. PubMed ID: 11205914
[TBL] [Abstract][Full Text] [Related]
11. In vivo cytokine responses to interleukin-2 immunotherapy after autologous stem cell transplantation in children with solid tumors.
Bönig H; Laws HJ; Wundes A; Verheyen J; Hannen M; Kim YM; Banning U; Nürnberger W; Körholz D
Bone Marrow Transplant; 2000 Jul; 26(1):91-6. PubMed ID: 10918410
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
[TBL] [Abstract][Full Text] [Related]
13. High-dose thiotepa with autologous bone marrow rescue in pediatric solid tumors.
Saarinen UM; Hovi L; Mäkipernaa A; Riikonen P
Bone Marrow Transplant; 1991 Nov; 8(5):369-76. PubMed ID: 1768972
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of interleukin-2 in children with cancer.
Roper M; Smith MA; Sondel PM; Gillespie A; Reaman GH; Hammond GD; Levitt D; Rosolen A; Colamonici OR; Neckers LM
Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):305-11. PubMed ID: 1456395
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of systemic recombinant interleukin-2 in the treatment of refractory nasopharyngeal carcinoma.
Chi KH; Myers JN; Chow KC; Chan WK; Tsang YW; Chao Y; Yen SH; Lotze MT
Oncology; 2001; 60(2):110-5. PubMed ID: 11244324
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of recombinant human interleukin-2 for pediatric malignancies: feasibility of outpatient therapy. A Pediatric Oncology Group Study.
Pais RC; Abdel-Mageed A; Ghim TT; Ode D; Melendez E; Kim HS; Findley H; Ragab AH
J Immunother (1991); 1992 Aug; 12(2):138-46. PubMed ID: 1504055
[TBL] [Abstract][Full Text] [Related]
17. Intensive chemotherapy with stem cell support-experience in pediatric solid tumours.
Pinkerton CR
Bull Cancer; 1995; 82 Suppl 1():61s-65s. PubMed ID: 7626856
[TBL] [Abstract][Full Text] [Related]
18. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial.
Blaney SM; Seibel NL; O'Brien M; Reaman GH; Berg SL; Adamson PC; Poplack DG; Krailo MD; Mosher R; Balis FM
J Clin Oncol; 1997 Apr; 15(4):1538-43. PubMed ID: 9193350
[TBL] [Abstract][Full Text] [Related]
20. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.
Rosenberg SA; Yannelli JR; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Parkinson DR; Seipp CA; Einhorn JH; White DE
J Natl Cancer Inst; 1994 Aug; 86(15):1159-66. PubMed ID: 8028037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
